Amplia Therapeutics Ltd (ATX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary

Amplia Therapeutics Ltd (Amplia Therapeutics), formerly Innate Therapeutics Ltd, is a pharmaceutical company with focus on the development of focal adhesion kinase (FAK) inhibitors for the treatment of cancer and fibrosis. Its lead drug candidate, AMP945, is a small molecule targeting focal adhesion kinase (FAK) in fibrotic tumors such as pancreatic and ovarian cancer; and the other drug candidate AMP886 is a multi-action molecule targeting VEGFR3 and FLT3 cancer pathways in solid and hematological cancers. As FAK is a significant target in cancer immunology, the company has focus on FAK inhibitors for treating cancers and chronic diseases such as idiopathic pulmonary fibrosis. Amplia Therapeutics is headquartered in Melbourne, Victoria, Australia.

Amplia Therapeutics Ltd (ATX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

it derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 5
List of Figures 5
Amplia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Amplia Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Amplia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Amplia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Amplia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Amplia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deal Details 11
Equity Offering 11
Innate Immunotherapeutics Raises USD1.5 Million in Private Placement of Shares 11
Innate Immunotherapeutics Raises USD0.2 Million in Private Placement of Shares 12
Innate Immunotherapeutics Raises USD1.9 Million in Private Placement of Shares 13
Innate Immunotherapeutics Raises USD2.3 Million in Rights Offering of Shares 15
Innate Immunotherapeutics Raises USD3 Million in Private Placement of Shares 17
Innate Immunotherapeutics Raises US8.95 Million Public Offering Of Shares 18
Innate Immunotherapeutics Completes IPO For US$9 Million 19
Acquisition 21
Innate Immunotherapeutics Completes Acquisition of Amplia Therapeutics 21
Amplia Therapeutics Ltd - Key Competitors 22
Amplia Therapeutics Ltd - Key Employees 23
Amplia Therapeutics Ltd - Locations And Subsidiaries 24
Head Office 24
Other Locations & Subsidiaries 24
Recent Developments 25
Financial Announcements 25
Jul 30, 2018: Innate Immunotherapeutics: 4C Quarterly Cash Flow Report of the year 2018 25
Corporate Communications 26
May 28, 2018: Innate Immunotherapeutics Names Dr. Warwick Tong As Chairman 26
Legal and Regulatory 27
Aug 08, 2018: Congressman Christopher Collins And Others Charged In Manhattan Federal Court With Insider Trading And Lying To Federal Law Enforcement Agents 27
Product News 30
06/21/2017: Innate Immunotherapeutics receives FDA clearance for MIS416 Investigational New Drug application 30
03/07/2017: Multiple Abstracts Concerning MIS416 Mechanism of Action Accepted for Presentation at Upcoming American Academy of Neurologists Meeting 31
Clinical Trials 32
Oct 20, 2017: Innate Immunotherapeutics Provides Corporate Update 32
Jul 21, 2017: No change to outcome of MIS416 trial in patients with SPMS following additional data analysis 33
Jun 27, 2017: Innate Immunotherapeutics announces top-line results for trial of MIS416 in patients with secondary progressive multiple sclerosis 34
Apr 20, 2017: Completion of Phase 2B trial of MIS416 in patients with secondary progressive multiple sclerosis 36
Feb 28, 2017: Phase 2B trial of MIS416 in patients with secondary progressive multiple sclerosis on schedule to complete by end of April 2017 37
Other Significant Developments 38
Sep 05, 2018: Innate Immunotherapeutics changes name to Amplia Therapeutics and ASX stock code to ATX 38
Oct 30, 2017: Innate Immunotherapeutics: 4C Quarterly Cash Flow Report 39
Jul 28, 2017: Innate Immunotherapeutics: 4C Quarterly Cash Flow Report 40
Appendix 41
Methodology 41
About GlobalData 41
Contact Us 41
Disclaimer 41

List Of Tables


Amplia Therapeutics Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Amplia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Amplia Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Amplia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Amplia Therapeutics Ltd, Deals By Therapy Area, 2012 to YTD 2018 9
Amplia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Innate Immunotherapeutics Raises USD1.5 Million in Private Placement of Shares 11
Innate Immunotherapeutics Raises USD0.2 Million in Private Placement of Shares 12
Innate Immunotherapeutics Raises USD1.9 Million in Private Placement of Shares 13
Innate Immunotherapeutics Raises USD2.3 Million in Rights Offering of Shares 15
Innate Immunotherapeutics Raises USD3 Million in Private Placement of Shares 17
Innate Immunotherapeutics Raises US8.95 Million Public Offering Of Shares 18
Innate Immunotherapeutics Completes IPO For US$9 Million 19
Innate Immunotherapeutics Completes Acquisition of Amplia Therapeutics 21
Amplia Therapeutics Ltd, Key Competitors 22
Amplia Therapeutics Ltd, Key Employees 23
Amplia Therapeutics Ltd, Subsidiaries 24

List Of Figures


Amplia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Amplia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Amplia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Amplia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Amplia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Amplia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Amplia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Amplia Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Amplia Therapeutics Ltd (ATX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Amplia Therapeutics Ltd (Amplia Therapeutics), formerly Innate Therapeutics Ltd, is a pharmaceutical company with focus on the development of focal adhesion kinase (FAK) inhibitors for the treatment of cancer and

USD 250 View Report

Kazia Therapeutics Ltd (KZA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Kazia Therapeutics Limited (Kazia Therapeutics), is a clinical stage biotechnology company which focuses on the discovery and development of anti-cancer drugs. It develops its products based on three drug technology

USD 250 View Report

Iksuda Therapeutics Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Iksuda Therapeutics Ltd (Iksuda), formerly Glythera Ltd is a biotechnology company that focuses on the development of antibody drug conjugates (ADCs) and biotherapeutics for the treatment of cancer. The company

USD 250 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available